Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1

Journal of Biological Chemistry

Volumn 287, Issue 18, 2012, Pages 14494-14501

  Mir, Shakeel U R ^a   Jin, Ling ^a   Craven, Rolf J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; CELL MEMBRANES; CHEMICAL ACTIVATION; RNA; TUMORS;

ANTIBODY ARRAYS; HISTONE DEACETYLASES; MATRIX METALLOPROTEINASE-9; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; PROGESTERONE RECEPTOR; SECRETED PROTEIN; TUMOR FORMATION; TUMOR INVASION;

PROTEINS;

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GELATINASE B; HISTONE DEACETYLASE INHIBITOR; HORMONE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KINASE B INHIBITOR; TRANSCRIPTION FACTOR RELA; TUMOR ASSOCIATED SIGMA 2 RECEPTOR; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL MEMBRANE; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

EID: 84860352374     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.324921     Document Type: Article

References (52)

1. Richardson, D. R. (2005) 24p3 and its receptor: dawn of a new iron age? Cell 123, 1175-1177
2. Devireddy, L. R., Gazin, C., Zhu, X., and Green, M. R. (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123, 1293-1305 (Pubitemid 41821786)
3. Yan, L., Borregaard, N., Kjeldsen, L., and Moses, M. A. (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276, 37258-37265
4. Nuntagowat, C., Leelawat, K., and Tohtong, R. (2010) NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin. Exp. Metastasis 27, 295-305
5. Tong, Z., Wu, X., Ovcharenko, D., Zhu, J., Chen, C. S., and Kehrer, J. P. (2005) Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 391, 441-448 (Pubitemid 41532443)
6. Iannetti, A., Pacifico, F., Acquaviva, R., Lavorgna, A., Crescenzi, E., Vascotto, C., Tell, G., Salzano, A. M., Scaloni, A., Vuttariello, E., Chiappetta, G., Formisano, S., and Leonardi, A. (2008) The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. U.S.A. 105, 14058-14063
7. Leng, X., Ding, T., Lin, H., Wang, Y., Hu, L., Hu, J., Feig, B., Zhang, W., Pusztai, L., Symmans, W. F., Wu, Y., and Arlinghaus, R. B. (2009) Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 69, 8579-8584
8. Tong, Z., Kunnumakkara, A. B., Wang, H., Matsuo, Y., Diagaradjane, P., Harikumar, K. B., Ramachandran, V., Sung, B., Chakraborty, A., Bresalier, R. S., Logsdon, C., Aggarwal, B. B., Krishnan, S., and Guha, S. (2008) Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 68, 6100-6108
9. Bolignano, D., Donato, V., Lacquaniti, A., Fazio, M. R., Bono, C., Coppolino, G., and Buemi, M. (2010) Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 288, 10-16
10. Li, S. H., Hawthorne, V. S., Neal, C. L., Sanghera, S., Xu, J., Yang, J., Guo, H., Steeg, P. S., and Yu, D. (2009) Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-κB activation. Cancer Res. 69, 9163-9168
11. Chen, L. f., Fischle, W., Verdin, E., and Greene, W. C. (2001) Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293, 1653-1657 (Pubitemid 32807844)
12. Falkenstein, E., Meyer, C., Eisen, C., Scriba, P. C., and Wehling, M. (1996) Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 229, 86-89 (Pubitemid 27013713)
13. Gerdes, D., Wehling, M., Leube, B., and Falkenstein, E. (1998) Cloning and tissue expression of two putative steroid membrane receptors. Biol. Chem. 379, 907-911 (Pubitemid 28369381)
14. Min, L., Strushkevich, N. V., Harnastai, I. N., Iwamoto, H., Gilep, A. A., Takemori, H., Usanov, S. A., Nonaka, Y., Hori, H., Vinson, G. P., and Okamoto, M. (2005) Molecular identification of adrenal inner zone antigen as a heme-binding protein. Febs. J. 272, 5832-5843 (Pubitemid 41689355)
15. Wehling, M., Schultz, A., and Lösel, R. (2007) To be or not to be (a receptor). Steroids 72, 107-110 (Pubitemid 46273490)
16. Mifsud, W., and Bateman, A. (2002) Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol. 3, RESEARCH0068
17. Min, L., Takemori, H., Nonaka, Y., Katoh, Y., Doi, J., Horike, N., Osamu, H., Raza, F. S., Vinson, G. P., and Okamoto, M. (2004) Characterization of the adrenal-specific antigen IZA (inner zone antigen) and its role in the steroidogenesis. Mol. Cell. Endocrinol. 215, 143-148 (Pubitemid 38333253)
18. Ghosh, K., Thompson, A. M., Goldbeck, R. A., Shi, X., Whitman, S., Oh, E., Zhiwu, Z., Vulpe, C., and Holman, T. R. (2005) Spectroscopic and biochemical characterization of heme binding to yeast Dap1p and mouse PGRMC1p. Biochemistry 44, 16729-16736 (Pubitemid 41832053)
19. Thompson, A. M., Reddi, A. R., Shi, X., Goldbeck, R. A., Moenne-Loccoz, P., Gibney, B. R., and Holman, T. R. (2007) Measurement of the heme affinity for yeast dap1p, and its importance in cellular function. Biochemistry 46, 14629-14637 (Pubitemid 350276368)
20. Hand, R. A., Jia, N., Bard, M., and Craven, R. J. (2003) Saccharomyces cerevisiae Dap1p, a novel DNA damage response protein related to the mammalian membrane-associated progesterone receptor. Eukaryot Cell 2, 306-317 (Pubitemid 36562370)
21. Crudden, G., Chitti, R. E., and Craven, R. J. (2006) Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J. Pharmacol. Exp. Ther. 316, 448-455 (Pubitemid 41832625)
22. Hughes, A. L., Powell, D. W., Bard, M., Eckstein, J., Barbuch, R., Link, A. J., and Espenshade, P. J. (2007) Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5, 143-149 (Pubitemid 46172917)
23. Mallory, J. C., Crudden, G., Johnson, B. L., Mo, C., Pierson, C. A., Bard, M., and Craven, R. J. (2005) Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae. Mol. Cell. Biol. 25, 1669-1679 (Pubitemid 40280136)
24. Craven, R. J., Mallory, J. C., and Hand, R. A. (2007) Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. J. Biol. Chem. 282, 36543-36551
25. Neubauer, H., Clare, S. E., Wozny, W., Schwall, G. P., Poznanovic, S., Stegmann, W., Vogel, U., Sotlar, K., Wallwiener, D., Kurek, R., Fehm, T., and Cahill, M. A. (2008) Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res. 10, R85
26. Ahmed, I. S., Rohe, H. J., Twist, K. E., Mattingly, M. N., and Craven, R. J. (2010) Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J. Pharmacol. Exp. Ther. 333, 564-573
27. Hand, R. A., and Craven, R. J. (2003) Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J. Cell. Biochem. 90, 534-547 (Pubitemid 37243701)
28. Ahmed, I. S., Rohe, H. J., Twist, K. E., and Craven, R. J. (2010) Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J. Biol. Chem. 285, 24775-24782
29. Xu, J., Zeng, C., Chu, W., Pan, F., Rothfuss, J. M., Zhang, F., Tu, Z., Zhou, D., Zeng, D., Vangveravong, S., Johnston, F., Spitzer, D., Chang, K. C., Hotchkiss, R. S., Hawkins, W. G., Wheeler, K. T., and Mach, R. H. (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380
30. Peluso, J. J., Pappalardo, A., Losel, R., and Wehling, M. (2006) Progesterone membrane receptor component 1 expression in the immature ratovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 147, 3133-3140 (Pubitemid 43764649)
31. Peluso, J. J., Pappalardo, A., Losel, R., and Wehling, M. (2005) Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability. Biol. Reprod. 73, 261-270 (Pubitemid 41022785)
32. Rohe, H. J., Ahmed, I. S., Twist, K. E., and Craven, R. J. (2009) PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation, and drug binding. Pharmacol. Ther. 121, 14-19
33. Crudden, G., Loesel, R., and Craven, R. J. (2005) Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol. 26, 142-146 (Pubitemid 41379753)
34. Peluso, J. J., Liu, X., Saunders, M. M., Claffey, K. P., and Phoenix, K. (2008) Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J. Clin. Endocrinol. Metab. 93, 1592-1599 (Pubitemid 351656493)
35. Dressman, H. K., Hans, C., Bild, A., Olson, J. A., Rosen, E., Marcom, P. K., Liotcheva, V. B., Jones, E. L., Vujaskovic, Z., Marks, J., Dewhirst, M. W., West, M., Nevins, J. R., and Blackwell, K. (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12, 819-826 (Pubitemid 43259863)
36. Peluso, J. J., Romak, J., and Liu, X. (2008) Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 149, 534-543 (Pubitemid 351159360)
37. Yoshitani, N., Satou, K., Saito, K., Suzuki, S., Hatanaka, H., Seki, M., Shinozaki, K., Hirota, H., and Yokoyama, S. (2005) A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements. Proteomics 5, 1472-1480 (Pubitemid 40593257)
38. Mallory, J. C., Crudden, G., Oliva, A., Saunders, C., Stromberg, A., and Craven, R. J. (2005) A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol. Pharmacol. 68, 1747-1756 (Pubitemid 41656027)
39. Delom, F., Emadali, A., Cocolakis, E., Lebrun, J. J., Nantel, A., and Chevet, E. (2007) Calnexin-dependent regulation of tunicamycin-induced apoptosis in breast carcinoma MCF-7 cells. Cell Death Differ. 14, 586-596
40. Borrás, C., Gómez-Cabrera, M. C., and Viña, J. (2011) The dual role of p53: DNA protection and antioxidant. Free Radic Res. 45, 643-652
41. Kroes, R. A., Abravaya, K., Seidenfeld, J., and Morimoto, R. I. (1991) Selective activation of human heat shock gene transcription by nitrosourea antitumor drugs mediated by isocyanate-induced damage and activation of heat shock transcription factor. Proc. Natl. Acad. Sci. U.S.A. 88, 4825-4829 (Pubitemid 21914635)
42. Ashburner, B. P., Westerheide, S. D., and Baldwin, A. S., Jr. (2001) The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21, 7065-7077 (Pubitemid 32916079)
43. Liu, Y., Smith, P. W., and Jones, D. R. (2006) Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol. Cell. Biol. 26, 8683-8696 (Pubitemid 44851930)
44. Chen, L. F., Williams, S. A., Mu, Y., Nakano, H., Duerr, J. M., Buckbinder, L., and Greene, W. C. (2005) NF-κB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25, 7966-7975 (Pubitemid 41262991)
45. Puig, S., Askeland, E., and Thiele, D. J. (2005) Coordinated remodeling of cellular metabolism during iron deficiency through targeted mRNA degradation. Cell 120, 99-110 (Pubitemid 40094606)
46. Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., and Hayakawa, T. (1992) Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J. Biol. Chem. 267, 21712-21719
47. Laurent-Matha, V., Derocq, D., Prébois, C., Katunuma, N., and Liaudet- Coopman, E. (2006) Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J. Biochem. 139, 363-371 (Pubitemid 43667100)
48. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (Pubitemid 34270240)
49. Bassères, D. S., Ebbs, A., Levantini, E., and Baldwin, A. S. (2010) Requirement of the NF-κB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70, 3537-3546
50. Ostenfeld, M. S., Fehrenbacher, N., Høyer-Hansen, M., Thomsen, C., Farkas, T., and Jäättelä, M. (2005) Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 65, 8975-8983 (Pubitemid 41377389)
51. Doyle, K., and Fitzpatrick, F. A. (2010) Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J. Biol. Chem. 285, 17417-17424
52. Crawford, K. W., and Bowen, W. D. (2002) Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62, 313-322 (Pubitemid 34074021)